Rigel Pharmaceuticals Inc $3.27

down -0.05


28/7/2014 02:39 PM  |  NASDAQ : RIGL  
Industries : Drugs / Drugs - Generic
Get Trend Analysis Icon Get RIGL Trend Analysis - it has underperformed the S&P 500 by 25%

Partner Headlines

  1. Rigel Initiates Phase 3 Studies Of Fostamatinib In ITP

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Earnings Scheduled For March 4, 2014

    Benzinga
  4. Benzinga's Top Pre-Market Losers

    Benzinga
  5. Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% ...

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Benzinga's Top Pre-Market Losers

    Benzinga
  8. UPDATE: Rigel Pharma Announces R343 Did Not Meet Primary, Secondary Endpoints ...

    Benzinga
  9. Weekly Preview: Earnings Season Nears The End, China in Focus

    Benzinga
  10. Stocks Open Firm But Reverse Lower On Fiscal Worries

    IBD
  11. Stocks Near Lows In Late Trading; Drug Stocks Sink

    IBD
  12. UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing ...

    Benzinga
  13. Mid-Day Market Update: Markets Go Red, SolarCity IPO a Success

    Benzinga
  14. UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following ...

    Benzinga
  15. Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint

    Benzinga
  16. Mid-Morning Market Update: Markets Cautiously Rising, Best Buy Boosts

    Benzinga
  17. Stocks Hitting 52-Week Lows

    Benzinga
  18. Morning Market Losers

    Benzinga
  19. Benzinga's Top Pre-Market Losers

    Benzinga
  20. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals

    Benzinga
  21. Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  22. UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Rigel ...

    Benzinga
  23. Rigel Announces Pricing Of 13.685M Share Public Offering at $9.50 per Share

    Benzinga
  24. Rigel Announces Proposed Public Offering Of Common Stock

    Benzinga
  25. Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  26. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  27. Piper Jaffray Reiterates Overweight on Rigel Pharmaceuticals ahead of Phase ...

    Benzinga
  28. Benzinga's Top Upgrades

    Benzinga
  29. Financial Breakfast: Morning News Summary for February 22, 2012

    Benzinga
Trading Center